Nephro-Urology Monthly

Published by: Kowsar

Association Between Metabolic Syndrome and Coronary Heart Disease in Patients on Hemodialysis

Mojgan Jalalzadeh 1 , Nouraddin Mousavinasab 2 , Mehrdad Soloki 3 , Reza Miri 4 , Mohammad Hassan Ghadiani 5 , * and Maryam Hadizadeh 6
Authors Information
1 Department of Nephrology, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
2 Department of Biostatistics, Mazandaran University of Medical Sciences, Sari, IR Iran
3 Department of Pulmonary, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
4 Department of Cardiology, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
5 Department of Nephrology, Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
6 Vice Chancellor, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
Article information
  • Nephro-Urology Monthly: January 01, 2015, 7 (1); e25560
  • Published Online: January 20, 2015
  • Article Type: Research Article
  • Received: November 24, 2014
  • Revised: December 18, 2014
  • Accepted: January 13, 2015
  • DOI: 10.5812/numonthly.25560

To Cite: Jalalzadeh M, Mousavinasab N, Soloki M, Miri R, Ghadiani M H, et al. Association Between Metabolic Syndrome and Coronary Heart Disease in Patients on Hemodialysis, Nephro-Urol Mon. 2015 ; 7(1):e25560. doi: 10.5812/numonthly.25560.

Abstract
Copyright © 2015, Nephrology and Urology Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Footnotes
References
  • 1. Meguid El Nahas A, Bello AK. Chronic kidney disease: the global challenge. Lancet. 2005; 365(9456): 331-40[DOI][PubMed]
  • 2. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003; 41(1): 1-12[DOI][PubMed]
  • 3. Chen J, Wildman RP, Gu D, Kusek JW, Spruill M, Reynolds K, et al. Prevalence of decreased kidney function in Chinese adults aged 35 to 74 years. Kidney Int. 2005; 68(6): 2837-45[DOI][PubMed]
  • 4. National Kidney F. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39(2 Suppl 1)-266[PubMed]
  • 5. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004; 351(13): 1296-305[DOI][PubMed]
  • 6. Muntner P, He J, Hamm L, Loria C, Whelton PK. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol. 2002; 13(3): 745-53[PubMed]
  • 7. Segura J, Campo C, Roldan C, Christiansen H, Vigil L, Garcia-Robles R, et al. Hypertensive renal damage in metabolic syndrome is associated with glucose metabolism disturbances. J Am Soc Nephrol. 2004; 15 Suppl 1-42[PubMed]
  • 8. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005; 112(17): 2735-52[DOI][PubMed]
  • 9. Alberti KG, Zimmet P, Shaw J, I. D. F. Epidemiology Task Force Consensus Group . The metabolic syndrome--a new worldwide definition. Lancet. 2005; 366(9491): 1059-62[DOI][PubMed]
  • 10. Grundy SM. Metabolic syndrome: a multiplex cardiovascular risk factor. J Clin Endocrinol Metab. 2007; 92(2): 399-404[DOI][PubMed]
  • 11. Kahn R, Buse J, Ferrannini E, Stern M, American Diabetes A, European Association for the Study of D. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2005; 28(9): 2289-304[PubMed]
  • 12. Reaven GM. The metabolic syndrome: is this diagnosis necessary? Am J Clin Nutr. 2006; 83(6): 1237-47[PubMed]
  • 13. Malik S, Wong ND, Franklin SS, Kamath TV, L'Italien GJ, Pio JR, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation. 2004; 110(10): 1245-50[DOI][PubMed]
  • 14. Young DO, Lund RJ, Haynatzki G, Dunlay RW. Prevalence of the metabolic syndrome in an incident dialysis population. Hemodial Int. 2007; 11(1): 86-95[DOI][PubMed]
  • 15. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002; 288(21): 2709-16[PubMed]
  • 16. Longenecker JC, Coresh J, Powe NR, Levey AS, Fink NE, Martin A, et al. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. J Am Soc Nephrol. 2002; 13(7): 1918-27[PubMed]
  • 17. National Cholesterol Education Program Expert Panel on Detection E, Treatment of High Blood Cholesterol in A. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106(25): 3143-421[PubMed]
  • 18. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001; 24(4): 683-9[PubMed]
  • 19. Onat A, Ceyhan K, Basar O, Erer B, Toprak S, Sansoy V. Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels--a prospective and cross-sectional evaluation. Atherosclerosis. 2002; 165(2): 285-92[PubMed]
  • 20. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation. 2003; 107(3): 391-7[PubMed]
  • 21. Expert Panel on Detection E, Treatment of High Blood Cholesterol in A. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001; 285(19): 2486-97[PubMed]
  • 22. Bruno G, Merletti F, Biggeri A, Bargero G, Ferrero S, Runzo C, et al. Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study. Diabetes Care. 2004; 27(11): 2689-94[PubMed]
  • 23. Shinohara K, Shoji T, Emoto M, Tahara H, Koyama H, Ishimura E, et al. Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. J Am Soc Nephrol. 2002; 13(7): 1894-900[PubMed]
  • 24. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int. 2003; 63(3): 793-808[DOI][PubMed]
  • 25. Hamada MA. Obesity and metabolic syndrome in Saudi hemodialysis patients. J Nephro Ren Transpl. 2009; 2(3): 18-27
  • 26. Garg A. Acquired and inherited lipodystrophies. N Engl J Med. 2004; 350(12): 1220-34[DOI][PubMed]
  • 27. Stolic R, Trajkovic G, Peric V, Jovanovic A, Stolic D, Sovtic S, et al. [Frequency and characteristics of metabolic disorders in patients on haemodialysis]. Vojnosanit Pregl. 2008; 65(3): 205-9[PubMed]
  • 28. Jalalzadeh M, Mohammadi R, Mirzamohammadi F, Ghadiani MH. Prevalence of metabolic syndrome in a hemodialysis population. Iran J Kidney Dis. 2011; 5(4): 248-54[PubMed]
  • 29. Bakker SJ, Gansevoort RT, de Zeeuw D. Metabolic syndrome: a fata morgana? Nephrol Dial Transplant. 2007; 22(1): 15-20[DOI][PubMed]
  • 30. Johnson DW, Armstrong K, Campbell SB, Mudge DW, Hawley CM, Coombes JS, et al. Metabolic syndrome in severe chronic kidney disease: Prevalence, predictors, prognostic significance and effects of risk factor modification. Nephrology (Carlton). 2007; 12(4): 391-8[DOI][PubMed]
  • 31. Bonora E, Targher G, Formentini G, Calcaterra F, Lombardi S, Marini F, et al. The Metabolic Syndrome is an independent predictor of cardiovascular disease in Type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study. Diabet Med. 2004; 21(1): 52-8[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments